A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 20 Mar 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 19 Mar 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.